P
Pulmatrix
Pulmatrix develops inhaled therapies for the treatment, prevention and transmission of infectious and progressive respiratory diseases
About Pulmatrix
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative inhaled therapies for serious pulmonary and non-pulmonary diseases. Utilizing its patented iSPERSE technology, Pulmatrix aims to enhance patient care by delivering therapeutics directly to the lungs. The company operates in the healthcare sector, primarily targeting patients with severe respiratory conditions. Pulmatrix's business model involves the research, development, and commercialization of its proprietary drug formulations. Revenue is generated through partnerships, licensing agreements, and eventual product sales. The company collaborates with partners like Sensory Cloud to market and distribute products such as FEND, an over-the-counter nasal hygiene product designed to suppress exhaled airborne particles. Pulmatrix's pipeline includes various therapeutic candidates aimed at addressing unmet medical needs in respiratory health.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2003
- Headquarters
- Lexington, United States
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Polaris Partners
5AM Ventures
Novartis Venture Fund
ARCH Venture Partners
Series B and later1 investor entered at this stage
Altitude Life Science Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pulmatrix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pulmatrix on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.